Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18549298 | 1.00 | NR1H2 (0.54) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL28698644 | 0.98 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL1334462 | 0.85 | HPGD (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL1335011 | 0.85 | HPGD (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL1334464 | 0.85 | HPGD (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL31309329 | 0.84 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL30059634 | 0.83 | NR1H2 (0.54) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL16759817 | 0.83 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL15764147 | 0.83 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL15764146 | 0.83 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637445-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026086812-A1 | INHIBITORS OF MENIN | RONGCHANG PHARMACEUTICALS, LTD. (CN) | 2026-04-30 | — | — | WO | disclosed |
| US-20260098029-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12540129-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12509442-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4007756-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12459932-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | ASKAT INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | ASKAT INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | ASKAT INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| EP-2379533-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | RaQualia Pharma Inc (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| WO-2010084767-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010084767-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2010-07-29 | — | — | WO | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509442-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIFC1 | NR1H2 305/4885USP2 2386/4885SMN1; SMN2 1308/4885 |
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | CNR1, CNR2, NPSR1 | NR1H2 45/4885USP2 3643/4885SMN1; SMN2 2761/4885 |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | NR1H2 137/4885USP2 730/4885SMN1; SMN2 3384/4885 |
| US-12637445-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF2C | NR1H2 487/4885USP2 2518/4885SMN1; SMN2 609/4885 |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | RIPK1, RIPK2, RIPK4 | NR1H2 1562/4885USP2 1821/4885SMN1; SMN2 1758/4885 |
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | NR1H2 1344/4885USP2 4021/4885SMN1; SMN2 1856/4885 |
| US-12459932-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | NR1H2 1885/4885USP2 2073/4885SMN1; SMN2 931/4885 |
| US-12540129-B2 | KIF18A inhibitors | KIF18A, KIFC1, KIF2C | NR1H2 639/4885USP2 3211/4885SMN1; SMN2 772/4885 |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | RIPK2, RIPK1, RIPK4 | NR1H2 3739/4885USP2 551/4885SMN1; SMN2 1842/4885 |
| US-20260098029-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIFC1 | NR1H2 369/4885USP2 2331/4885SMN1; SMN2 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.